Key Highlights

  • USD 1.38 to USD 1.46 is the third quarter adjusted EPS guidance for Abbott Laboratories (NYSE:ABT), against USD 1.30 a year earlier. The USD 1.42 midpoint implies about 9.2 percent growth, simple arithmetic. Results arrive October 21, 2026 before the open.
  • USD 12.593 billion was second quarter sales, up 13.0 percent reported but only 4.8 percent comparable. The gap comes from the March 23, 2026 Exact Sciences acquisition, so investors in Abbott Laboratories (NYSE:ABT) should focus on comparable growth, not headline growth.
  • USD 104.68 was the October 15 close for Abbott Laboratories (NYSE:ABT), up 2.29 percent, in a 52-week range of USD 81.97 to USD 132.03. Barclays initiated at Overweight with a USD 120 target on October 7, and Redburn upgraded to Buy at USD 127.
  • 18.05 percent is Abbott's weight in the iShares U.S. Medical Devices ETF (NYSEARCA:IHI), which rose 2.47 percent on October 15 to USD 54.01. The fund lost 8.71 percent over one year, so devices have lagged the sector rally in published data.

What the Company Has Guided

At second quarter results on July 16, 2026, Abbott raised full-year adjusted EPS guidance to USD 5.45 to USD 5.60 from USD 5.38 to USD 5.58 and reaffirmed comparable sales growth of 6.5 to 7.5 percent. Chairman and chief executive Robert Ford expects accelerating sales and earnings growth in the second half. Published consensus puts third quarter revenue near USD 13.0 billion, about 14 percent above USD 11.393 billion a year earlier (simple arithmetic), much of it acquisition-driven.

Segments to Watch

Diabetes Care sold USD 2.188 billion in the second quarter, with continuous glucose monitors up 9.5 percent comparable. Electrophysiology grew in the low teens. Cancer Diagnostics, which includes Exact Sciences, delivered USD 919 million, up 13.3 percent comparable, while Rapid and Molecular Diagnostics fell 8.0 percent. Nutrition fell 3.6 percent comparable. Comparable growth restates prior-year sales to include the acquired business, which is why it differs sharply from reported growth of 13.0 percent.

Risks and Benchmarks

Adjusted EPS grew 4.0 percent to USD 1.31 in the second quarter, so the third quarter guide needs roughly double that pace. Analyst previews flag a tough comparison, a still-shrinking Nutrition unit, pressure in United States structural heart, reimbursement dependence for glucose monitors and integration of Exact Sciences. A forward price-to-earnings ratio of 18.06 in published data and a market value of USD 181.14 billion leave the stock exposed to a miss.

Where Things Stand

It depends. Abbott Laboratories (NYSE:ABT) can deliver the USD 1.38 to USD 1.46 guide only if second half acceleration shows up in glucose monitors, electrophysiology and cancer diagnostics while Nutrition stabilizes. The evidence is mixed: raised full-year EPS guidance and two bullish analyst moves support the case, but second quarter comparable growth of 4.8 percent and EPS growth of 4.0 percent are well below what the guide implies. Results on October 21, 2026 before the open, and the 9:00 a.m. ET call, will show whether organic growth is accelerating.